Sonrotoclax
Sonrotoclax 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Chronic Lymphocytic Leukemia、Small Lymphocytic Leukemia、CLL、Mantle Cell Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
20 项
全球在招研究
4 项
已进入 III/IV 期
22 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Alliance for Clinical Trials in Oncology
- BeOne Medicines
- Christine Ryan
- M.D. Anderson Cancer Center
- Fred Hutchinson Cancer Center
- German CLL Study Group
- The First Affiliated Hospital with Nanjing Medical University
- Canadian Cancer Trials Group
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Argentina、澳大利亚、奥地利、Brazil、中国、法国、德国、意大利、日本、新西兰、Poland
正在招募患者的 Sonrotoclax 研究
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
II 期招募中美国NCT06854003A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
III 期招募中美国Argentina澳大利亚奥地利NCT06742996A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
I 期 / II 期招募中美国澳大利亚Brazil中国NCT06634589A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
II 期招募中美国NCT07508995Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
II 期招募中美国NCT06839053Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter Transformation
II 期招募中奥地利丹麦德国NCT04271956A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
II 期招募中中国NCT07671378Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
II 期招募中加拿大NCT07341191Study of SA+X in the Treatment of Newly Diagnosed AML
II 期招募中中国NCT07548710A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
III 期招募中美国Argentina澳大利亚奥地利NCT06943872A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
I 期 / II 期招募中美国澳大利亚Brazil中国NCT06697184Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
II 期招募中美国NCT06849713Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
I 期招募中美国NCT06859008A Study of BGB-11417 in Participants With Myeloid Malignancies
I 期 / II 期招募中美国澳大利亚中国法国NCT04771130Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
II 期招募中中国NCT07335887A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
III 期招募中美国澳大利亚Brazil加拿大NCT07277231A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
I 期 / II 期招募中美国澳大利亚Brazil加拿大NCT04973605Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
III 期招募中美国NCT07321652Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
II 期招募中中国NCT06463691Sonrotoclax Plus Azacitidine in Patients With MDS-IB2
I 期 / II 期招募中中国NCT07885397
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。